Literature DB >> 28372990

Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease.

Magdalena J Kiprowska1, Anna Stepanova2, Dustin R Todaro3, Alexander Galkin4, Arthur Haas3, Scott M Wilson5, Maria E Figueiredo-Pereira6.   

Abstract

In Alzheimer's disease proteasome activity is reportedly downregulated, thus increasing it could be therapeutically beneficial. The proteasome-associated deubiquitinase USP14 disassembles polyubiquitin-chains, potentially delaying proteasome-dependent protein degradation. We assessed the protective efficacy of inhibiting or downregulating USP14 in rat and mouse (Usp14axJ) neuronal cultures treated with prostaglandin J2 (PGJ2). IU1 concentrations (HIU1>25μM) reported by others to inhibit USP14 and be protective in non-neuronal cells, reduced PGJ2-induced Ub-protein accumulation in neurons. However, HIU1 alone or with PGJ2 is neurotoxic, induces calpain-dependent Tau cleavage, and decreases E1~Ub thioester levels and 26S proteasome assembly, which are energy-dependent processes. We attribute the two latter HIU1 effects to ATP-deficits and mitochondrial Complex I inhibition, as shown herein. These HIU1 effects mimic those of mitochondrial inhibitors in general, thus supporting that ATP-depletion is a major mediator of HIU1-actions. In contrast, low IU1 concentrations (LIU1≤25μM) or USP14 knockdown by siRNA in rat cortical cultures or loss of USP14 in cortical cultures from ataxia (Usp14axJ) mice, failed to prevent PGJ2-induced Ub-protein accumulation. PGJ2 alone induces Ub-protein accumulation and decreases E1~Ub thioester levels. This seemingly paradoxical result may be attributed to PGJ2 inhibiting some deubiquitinases (such as UCH-L1 but not USP14), thus triggering Ub-protein stabilization. Overall, IU1-concentrations that reduce PGJ2-induced accumulation of Ub-proteins are neurotoxic, trigger calpain-mediated Tau cleavage, lower ATP, E1~Ub thioester and E1 protein levels, and reduce proteasome activity. In conclusion, pharmacologically inhibiting (with low or high IU1 concentrations) or genetically down-regulating USP14 fail to enhance proteasomal degradation of Ub-proteins or Tau in neurons.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's; Calpain; Deubiquitinase; Mitochondria; Tau; USP14; Ubiquitin-activating enzyme

Mesh:

Substances:

Year:  2017        PMID: 28372990      PMCID: PMC5549686          DOI: 10.1016/j.bbadis.2017.03.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  86 in total

1.  Ubiquitin homeostasis is critical for synaptic development and function.

Authors:  Ping-Chung Chen; Bula J Bhattacharyya; John Hanna; Heather Minkel; Julie A Wilson; Daniel Finley; Richard J Miller; Scott M Wilson
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 2.  Necrotic death as a cell fate.

Authors:  Wei-Xing Zong; Craig B Thompson
Journal:  Genes Dev       Date:  2006-01-01       Impact factor: 11.361

3.  Assessment of proteasome impairment and accumulation/aggregation of ubiquitinated proteins in neuronal cultures.

Authors:  Natura Myeku; Maria Jose Metcalfe; Qian Huang; Maria Figueiredo-Pereira
Journal:  Methods Mol Biol       Date:  2011

4.  Major changes in complex I activity in mitochondria from aged rats may not be detected by direct assay of NADH:coenzyme Q reductase.

Authors:  M L Genova; C Castelluccio; R Fato; G Parenti Castelli; M Merlo Pich; G Formiggini; C Bovina; M Marchetti; G Lenaz
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

5.  Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction.

Authors:  Y Liu; D A Peterson; H Kimura; D Schubert
Journal:  J Neurochem       Date:  1997-08       Impact factor: 5.372

6.  Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome.

Authors:  Takeshi Ishii; Toyo Sakurai; Hiroko Usami; Koji Uchida
Journal:  Biochemistry       Date:  2005-10-25       Impact factor: 3.162

7.  Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease.

Authors:  Scott M Wilson; Bula Bhattacharyya; Rivka A Rachel; Vincenzo Coppola; Lino Tessarollo; Deborah B Householder; Colin F Fletcher; Richard J Miller; Neal G Copeland; Nancy A Jenkins
Journal:  Nat Genet       Date:  2002-10-07       Impact factor: 38.330

8.  An endogenous electrophile that modulates the regulatory mechanism of protein turnover: inhibitory effects of 15-deoxy-Delta 12,14-prostaglandin J2 on proteasome.

Authors:  Takahiro Shibata; Takaaki Yamada; Mitsuhiro Kondo; Nobuyuki Tanahashi; Keiji Tanaka; Hajime Nakamura; Hiroshi Masutani; Junji Yodoi; Koji Uchida
Journal:  Biochemistry       Date:  2003-12-02       Impact factor: 3.162

Review 9.  Regulation of proteolysis by human deubiquitinating enzymes.

Authors:  Ziad M Eletr; Keith D Wilkinson
Journal:  Biochim Biophys Acta       Date:  2013-07-09

10.  Novel phosphorylation and ubiquitination sites regulate reactive oxygen species-dependent degradation of anti-apoptotic c-FLIP protein.

Authors:  Rachel P Wilkie-Grantham; Shu-Ichi Matsuzawa; John C Reed
Journal:  J Biol Chem       Date:  2013-03-21       Impact factor: 5.157

View more
  20 in total

Review 1.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

Review 2.  Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Authors:  Christine S Muli; Wenzhi Tian; Darci J Trader
Journal:  Chembiochem       Date:  2019-05-24       Impact factor: 3.164

Review 3.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

4.  Prostaglandin J2 promotes O-GlcNAcylation raising APP processing by α- and β-secretases: relevance to Alzheimer's disease.

Authors:  Teneka Jean-Louis; Patricia Rockwell; Maria E Figueiredo-Pereira
Journal:  Neurobiol Aging       Date:  2017-11-14       Impact factor: 4.673

5.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

6.  Sustained ER stress promotes hyperglycemia by increasing glucagon action through the deubiquitinating enzyme USP14.

Authors:  Bin Liu; Zhijian Zhang; Yanyun Hu; Yan Lu; Duanzhuo Li; Jie Liu; Shengjie Liao; Min Hu; Yuxing Wang; Die Zhang; Yulu Chen; Qilan Qian; Xianfeng Lv; Duojiao Wu; Minjia Tan; Cheng Hu; Xuelian Xiong; Xiaoying Li
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-08       Impact factor: 11.205

7.  An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons.

Authors:  Monica Boselli; Byung-Hoon Lee; Jessica Robert; Miguel A Prado; Sang-Won Min; Chialin Cheng; M Catarina Silva; Changhyun Seong; Suzanne Elsasser; Ketki M Hatle; Timothy C Gahman; Steven P Gygi; Stephen J Haggarty; Li Gan; Randall W King; Daniel Finley
Journal:  J Biol Chem       Date:  2017-09-26       Impact factor: 5.157

Review 8.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

Review 9.  Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases.

Authors:  Baohua Liu; Jing Ruan; Meng Chen; Zhongding Li; Gloria Manjengwa; Dirk Schlüter; Weihong Song; Xu Wang
Journal:  Mol Psychiatry       Date:  2021-07-20       Impact factor: 15.992

Review 10.  Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential.

Authors:  Jun-Nan Guo; Bai-Rong Xia; Shen-Hui Deng; Chang Yang; Ya-Nan Pi; Bin-Bin Cui; Wei-Lin Jin
Journal:  Front Cell Dev Biol       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.